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operative times were predictive for VTE during hospitaliza-
tion, but not for post-discharge events. Admission two or 
more days before surgery was predictive for DVT, but not for 
PE. Preoperative steroid usage and male gender were predic-
tive for post-discharge DVT and PE, respectively. ICH was 
associated with various comorbidities and longer operative 
times. This multicenter study demonstrates distinct critical 
time periods for the development of thrombotic and hemor-
rhagic events after craniotomy. Furthermore, the VTE risk 
profile depends on the type of VTE (DVT vs. PE) and clini-
cal setting (hospitalized vs. post-discharge patients).
Keywords Deep venous thrombosis · Intracranial 
hemorrhage · Primary malignant brain tumor · Pulmonary 
embolism · Venous thromboembolism
Introduction
Venous thromboembolism (VTE), including deep venous 
thrombosis (DVT) and pulmonary embolism (PE), is a major 
cause of morbidity and mortality in patients undergoing crani-
otomy for primary malignant brain tumors [1–6]. In addition to 
known surgical risk factors, such as venous stasis from periop-
erative immobility, endothelial injury, and inflammation from 
the operation itself, cancer is a recognized risk factor for VTE 
development [7]. Among all cancer types, high-grade gliomas 
have been shown to result in second highest lifetime risk for 
cancer-related VTE, one of the highest risks of perioperative 
VTE and, when comparing craniotomy for any brain tumor to 
craniotomy for non-neoplastic disease, rates of postoperative 
VTE have been reported to be twice as high [8–11]. VTE has 
been reported as one of the most frequent major complications 
after craniotomy for brain tumors with incidences up to 21% 
in the first 3 months after surgery [1–6].
Abstract Venous thromboembolism (VTE), including 
deep venous thrombosis (DVT) and pulmonary embolism 
(PE), frequently complicates the postoperative course of 
primary malignant brain tumor patients. Thromboprophy-
lactic anticoagulation is commonly used to prevent VTE at 
the risk of intracranial hemorrhage (ICH). We extracted all 
patients who underwent craniotomy for a primary malignant 
brain tumor from the National Surgical Quality Improve-
ment Program (NSQIP) registry (2005–2015) to perform 
a time-to-event analysis and identify relevant predictors of 
DVT, PE, and ICH within 30 days after surgery. Among the 
7376 identified patients, the complication rates were 2.6, 
1.5, and 1.3% for DVT, PE, and ICH, respectively. VTE 
was the second-most common major complication and third-
most common reason for readmission. ICH was the most 
common reason for reoperation. The increased risk of VTE 
extends beyond the period of hospitalization, especially for 
PE, whereas ICH occurred predominantly within the first 
days after surgery. Older age and higher BMI were overall 
predictors of VTE. Dependent functional status and longer 
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Previous studies have identified older age, male sex, His-
panic ethnicity, history of craniotomy, history of VTE, con-
gestive heart failure, coagulopathy, seizures, increased stay 
on the intensive care unit, prolonged hospital stay, medium 
bed size, residual tumor tissue, and absence of thrombo-
prophylactic therapy as predictors of VTE after craniotomy 
for primary malignant brain tumors [3, 4, 6, 12–15]. Most 
of these studies have been small, single-center studies, and 
none of these studies have identified predictors or performed 
time-to-event analyses separated for VTE type (DVT vs. 
PE) and the clinical setting (hospitalized vs. post-discharge 
patients).
Most patients undergoing surgery for brain tumors receive 
pharmaceutic prophylaxis in combination with mechanical 
prophylaxis in the perioperative setting [16–19]. However, 
anticoagulation increases the risk of intracranial hemorrhage 
(ICH), which is one of the most frequent and feared compli-
cations in patients undergoing operations for brain tumors 
[20]. The increased risk of ICH makes the use of prophy-
lactic anticoagulation an issue of great debate and careful 
balance in this patient population. Although the incidence of 
ICH is lower compared to VTE events, their outcomes can 
be at least as detrimental. Only few predictors associated 
with ICH have been identified including history of crani-
otomy, use of bevacizumab, and therapeutic anticoagula-
tion for a VTE [13, 20–24]. Adequate assessment of the 
perioperative risk of both VTE and ICH among this patient 
population, as well as accurately predicting the typical time 
to a thrombotic or hemorrhagic event, is meaningful in tai-
loring postoperative management to the risk profile of the 
individual patient.
The American College of Surgeons (ACS) National 
Surgical Quality Improvement Program (NSQIP) database 
registers follow-up of neurosurgical patients for 30 days 
postoperatively, and reports variables relevant to this issue, 
including the occurrence of DVT, PE, and ICH with related 
time-to-event data. Because the risk of ICH is intimately 
tied to the thromboprophylactic treatment used for patients 
with brain tumors, this study addresses thrombotic as well as 
hemorrhagic complications. In this study, NSQIP was used 
to identify predictors and perform time-to-event analyses for 
VTE and ICH. Assessment of VTE was stratified for VTE 




The NSQIP includes surgical patients from over 600 par-
ticipating hospitals in the U.S. operated on from 2005 to 
2015. This validated dataset is collected by trained surgical 
reviewers using a standardized protocol, and includes com-
mon postoperative complications, occurrence of reopera-
tions and readmissions, together with associated reasons and 
time-to-event in days. The NSQIP registry has previously 
been used to study outcomes after neurosurgical procedures 
[25–36]. Our institutional review board has exempted the 
NSQIP database from review.
Inclusion criteria
Patients were included who met the following criteria: (1) 
age 18 years or older; (2) a Current Procedural Terminol-
ogy (CPT) code indicating craniotomy for surgical resection 
of brain tumor (CPT: 61500, 61510, 61512, 61518, 61519, 
61520, 61521, 61526, and 61530); (3) a postoperative diag-
nosis indicative of primary malignant brain tumor (Interna-
tional Classification of Diseases, Ninth Revision [ICD-9]: 
191.x).
Covariates
Age, body mass index (BMI), and operative time were 
assessed continuously in years, kg/m2, and minutes, respec-
tively. Other categorized pre- and perioperative covariates 
included sex, race, American Society of Anesthesiologists 
(ASA)-classification (I–II, III or IV–V), functional status 
(dependent or independent), smoking within 1 year prior 
to surgery, history of hypertension requiring medication, 
chronic heart failure, COPD, renal failure, dialysis, insulin 
dependent diabetes, bleeding disorder, weight loss (> 10% 
loss of body weight in the 6 months prior to surgery), dysp-
nea, ventilator dependence, steroid usage, emergency clas-
sification, transfer status (admitted from home vs. not from 
home), creatinine (< 1.4 vs. ≥ 1.4 mg/dL), hematocrit (< 36 
vs. ≥36%), platelet count (100–450/µm3, < 100/µm3, vs. 
> 450/µm3), sodium (135–145 mEq/L, < 135 mEq/L, vs. 
> 145 mEq/L), white blood cell (WBC) count (≤ 12,000/
µL vs. > 12,000/µL), preoperative transfusion, preoperative 
systemic inflammatory response syndrome, admission two 
or more days before surgery, and anesthesia type (general vs. 
no general anesthesia).
Missing data
Covariates with more than 10% missing data or occurring 
in less than 1% of cases were excluded from multivariable 
analysis. Cases with missing data in one of the variables of 
the multivariable analysis were excluded from the analysis. 
A confirmatory analysis was performed for every multivaria-
ble model, in which missing data was coded as an additional 
group to verify if missing data affected the results.
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Outcomes
VTE was defined as the occurrence of DVT or PE within 30 
days after surgery. The occurrence of other major compli-
cations and reasons for readmission and reoperation were 
extracted by means of ICD-9 and CPT codes, to assess the 
relative contribution of VTE and ICH to morbidity, read-
mission, and reoperation. Based on a previously published 
definition, major complications were defined as either acute 
renal failure, cardiac arrest, death, failure to wean from 
ventilator, myocardial infarction, reintubation, reoperation, 
stroke, VTE, sepsis, and surgical site infection [37]. ICH 
was defined as the occurrence of an ICH requiring surgical 
evacuation and extracted by means of CPT and ICD-9 codes. 
Reasons for reoperation including ICH were collected since 
2012.
Statistical analysis
Statistical analyses were conducted using R 3.3.3 (R Core 
Team, Auckland, New Zealand). Univariable analysis was 
performed using logistic regression. Each primary throm-
botic outcome (VTE, DVT, PE) was assessed for its occur-
rence during the initial hospital stay, after discharge, and 
within 30 days overall. ICH was assessed within 30 days 
overall. Potential predictors were selected for inclusion in 
the multivariable logistic regression analysis based on uni-
variable analysis for each outcome. Only pre- and intraop-
erative factors were included in the multivariable analysis, 
because inclusion of postoperative complications other than 
VTE or ICH would reduce the timeframe in which com-
plications can be detected due to the limited 30-day col-
lection timeframe of NSQIP, thereby biasing the results of 
the model. Potential predictors were excluded from the final 
model if they demonstrated multicollinearity or had a rela-
tive low contribution to model fit. A p value below 0.05 was 
considered statistically significant. Bonferroni correction for 
multiple testing was deemed to be too rigorous due to the 
low number of events. The β-coefficients of the continu-
ous variables in the final model were multiplied to represent 
the odds ratios and confidence intervals of meaningful and 
interpretable units for age (per 10 years increase), BMI (per 
5 kg/m2 increase), and operative time (per 60 min increase).
Results
Demographics of study population
The NSQIP registry provided 7376 patients who underwent 
craniotomy for resection of a primary malignant brain tumor 
during the study period. Comorbidities, demographics, and 
preoperative laboratory values are shown separated by the 
occurrence of VTE (Table 1).
Outcomes
Of the 7376 patients that were identified, 257 (3.5%) devel-
oped a VTE within 30 days after surgery, of which 91 
(36%) occurred within the initial hospital stay. VTE was 
the second-most common major complication and included 
192 DVTs (2.6%) and 107 PEs (1.5%). Forty-two patients 
developed both DVT and PE (0.6%). The rate of DVT was 
highest within the first 2 weeks after surgery, whereas the 
rate of PE was fairly consistent throughout the first month, 
occurring predominantly post-discharge (Fig. 1a, b). The 
rate of VTE was more than twice as high (7.0 vs. 3.2%, 
p < 0.001) among patients with a preoperative dependent 
functional status compared to patients with an independent 
functional status (Fig. 1c).
The median length of stay among VTE patients was 8 
days (inter-quartile range [IQR] 5–16 days) compared to 
4 days (IQR 3–8 days) in non-VTE patients (Fig. 1d). In-
hospital VTE occurred at a median of 6 days (IQR 3–8 days) 
after surgery, and patients were discharged at a median of 
8 days after the occurrence of VTE (IQR 3–16 days). Post-
discharge VTE occurred at a median of 13 days after dis-
charge (IQR 6–19 days) and resulted in 25% of cases in 
readmission, making VTE the third-most common reason 
for readmission (7.4% of total readmissions). Of the patients 
that developed a PE, 35 (32.7%) were preceded by a DVT. 
Post-discharge PEs were less frequently preceded by a DVT 
than hospital acquired PEs (26 vs. 48%, p = 0.048).
Of the 5699 patients that were identified in the NSQIP 
registry 2012–2015 with data on reoperation and associ-
ated reasons, 72 (1.3%) developed an ICH requiring sur-
gical evacuation at a median of 2 days after surgery (IQR 
0–7.5 days) (Fig. 1e). ICH was the most common reason for 
reoperation (18.5% of the total number of reoperations). The 
median length of stay among ICH patients was 12 days (IQR 
6–21 days) compared to 4 days (IQR 3–8 days) in non-ICH 
patients (Fig. 1f). The 55 patients (77.5%) that developed 
an ICH during the initial hospital stay, were discharged at a 
median of 10 days (IQR 6–19) after the occurrence of ICH.
Multivariable analysis
Older age and higher BMI were found to be risk factors of 
VTE overall (Tables 2, 3). Dependent functional status and 
longer operative times were predictive for hospital VTE, 
but not for post-discharge events. Admission two or more 
days before surgery was a predictor of DVT, but not for PE. 
Steroid usage was predictive for post-discharge DVT, and 
male gender was predictive for post-discharge PE. Higher 
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Table 1  Demographics and preoperative comorbidities of NSQIP patients undergoing craniotomy for glioma, compared by VTE occurrence
Bold p-values below 0.05 were considered as statistically significant
ASA American Society of Anesthesiologists, CI confidence interval, CHF congestive heart failure, SIRS systematic inflammatory response syn-
drome, WBC white blood cell count
a Inflated β-coefficients to odds ratio per 10 years increase
b Inflated β-coefficients to odds ratio per 5 kg/m2 increase
c Inflated β-coefficients to odds ratio per 60 min increase
d Infinity due to 0 count in one of the cells






Odd ratio 95% CI p value
Age Years ± SD 54.5 ± 15.6 54.4 ± 15.6 59.4 ± 15.7 1.25a 1.15–1.36 < 0.001
Gender Female 42.3 42.3 41.6 Ref – –
Male 57.7 57.7 58.4 1.03 0.91–1.19 0.82
Race White 91.7 91.7 94.8 Ref – –
Black 4.8 4.8 4.2 0.85 0.40–1.60 0.66
Asian 3.0 3.0 0.5 0.15 0.01–0.67 0.04
Other 0.5 0.5 0.5 0.95 0.05–4.51 0.96
ASA Classification I–II 27.7 28.1 18.3 Ref – –
III 59.2 59.0 65.5 1.71 1.23–2.40 0.002
IV–V 13.0 12.9 16.3 1.94 1.26–2.97 0.002
BMI kg/m2 ± SD 28.4 ± 6.2 28.4 ± 6.2 29.8 ± 6.3 1.19b 1.08–1.30 < 0.001
Smoking 17.1 17.4 10.1 0.53 0.35–0.78 0.003
Emergency case 6.5 6.5 8.9 1.42 0.89–2.15 0.12
Admitted not from home 18.1 18.4 24.2 1.42 1.05–1.89 0.02
Hypertension 35.4 35.1 43.6 1.43 1.11–1.83 0.006
History of COPD 2.4 2.3 3.1 1.35 0.60–2.59 0.42
History of CHF 0.2 0.2 0.8 3.48 0.55–12.32 0.10
Renal Failure 0.1 0.1 0.4 4.63 0.24–27.24 0.16
Dialysis 0.1 0.1 0.0 Inf.d Inf.d 1.000
Ventilator dependence 1.1 1.1 3.1 2.98 1.31–5.86 0.004
Weight loss 1.7 1.7 1.6 0.93 0.28–2.23 0.89
Bleeding disorder 2.2 2.1 3.1 1.46 0.65–2.82 0.30
Dyspnea 2.6 2.6 2.7 1.07 0.45–2.12 0.87
Insulin-dependent diabetes 3.9 3.8 4.7 1.23 0.65–2.13 0.49
Preoperative steroid usage 16.6 16.4 23.3 1.55 1.15–2.07 0.004
Dependent functional status 5.1 5.0 10.4 2.23 1.43–3.32 < 0.001
Preoperative SIRS 3.6 3.4 5.1 1.51 0.81–2.56 0.16
Preoperative transfusion 0.2 0.2 0.4 1.85 0.10–9.18 0.55
Preoperative Sodium 135–145 89.9 90.0 87.2 Ref – –
< 135 9.1 9.0 10.8 1.24 0.80–1.83 0.31
> 145 1.0 1.0 2.0 2.07 0.72–4.69 0.12
Preoperative creatinine ≥ 1.4 mg/dL 4.4 4.6 4.4 0.96 0.49–1.69 0.90
Preoperative WBC > 12,000/µL 24.8 24.4 33.1 1.53 1.16–1.99 0.002
Preoperative Hematocrit < 36% 11.9 11.8 12.6 1.07 0.72–1.54 0.71
Platelets 100–450 97.5 97.6 95.7 Ref – –
< 100 1.3 1.0 2.8 2.29 0.95–4.65 0.05
> 450 1.2 1.2 1.6 1.37 0.41–3.33 0.54
Operative time Minutes [IQR] 179 [123–250] 179 [123–250] 191 [134–252] 1.33c 1.02–1.74 0.04
No general anesthesia 5.9 5.9 5.4 0.91 0.50–1.52 0.74
Admission to operation ≥ 2 days 32.8 32.4 46.3 1.80 1.40–2.31 < 0.001
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Fig. 1  Number of patients per day in the total population devel-
oping a deep venous thrombosis (a), pulmonary embolism (b) or 
intracranial hemorrhage (e) after craniotomy stratified for timing of 
diagnosis. Distribution of length of postoperative stay compared by 
the occurrence of VTE (d) and ICH (f). Frequency of VTE and ICH 
compared by functional status (c)
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ASA-classification, hypertension, weight loss, bleeding dis-
orders, preoperative sodium < 135 mEq/L, and longer opera-
tive times were found to be predictors of postoperative ICH 
requiring surgical evacuation (Table 4).
Discussion
VTE is one of the most common major complications and 
reasons for readmission, and ICH the most common rea-
son for reoperation among patients undergoing craniotomy 
for primary malignant brain tumors. This multicenter study 
provides novel and useful information regarding the tim-
ing of these events and identification of high-risk patients. 
The increased risk of VTE extends beyond the period of 
hospitalization, especially for PE, whereas ICH occurs pre-
dominantly within the first days after surgery. The VTE risk 
Table 2  Multivariable analysis comparing risk profiles for DVT occurring in-hospital (n = 69) versus post-discharge (n = 123) and PE occurring 
in-hospital (n = 29) versus post-discharge (n = 78)
Bold p-values below 0.05 were considered as statistically significant
BMI body mass index, DVT deep venous thrombosis, OR operation room, PE pulmonary embolism, WBC white blood cell count
Predictors In-hospital DVT Post-discharge DVT
OR 95% CI p value OR 95% CI p value
Age per 10 years increase 1.28 1.06–1.55 0.01 1.28 1.12–1.47 < 0.001
BMI per 5 kg/m2 increase 1.23 1.01–1.46 0.03 1.25 1.09–1.41 < 0.001
Dependent functional status 2.63 1.18–5.27 0.01 0.82 0.34–1.68 0.62
Preoperative WBC > 12,000/µL 1.76 1.00–2.97 0.05 1.05 0.69–1.57 0.80
Steroid usage 1.38 0.71–2.52 0.32 2.17 1.39–3.30 < 0.001
Admission to operation ≥ 2 days 1.85 1.08–3.19 0.02 2.02 1.37–2.98 < 0.001
OR time per 60 min increase 1.26 1.13–1.39 < 0.001 1.04 0.94–1.15 0.40
Predictors In-hospital PE Post-discharge PE
OR 95% CI p value OR 95% CI p value
Age per 10 years increase 1.08 0.84–1.41 0.56 1.33 1.13–1.58 < 0.001
Male gender 0.93 0.43–2.04 0.85 2.32 1.38–4.07 0.002
BMI per 5 kg/m2 increase 1.27 0.97–1.62 0.07 1.24 1.04–1.46 0.01
Dependent functional status 5.46 1.96–13.12 < 0.001 2.15 0.94–4.31 0.05
OR time per 60 min increase 1.24 1.06–1.43 0.004 1.10 0.98–1.23 0.10
Table 3  Overview overall and specific risk factors for VTE
This study was underpowered to identify specific risk factors of in-
hospital PEs







DVT Admission ≥ 2 days pre-op
Longer operative times
Dependent functional status
Admission ≥ 2 days pre-op
Steroid usage
PE Longer operative times
Dependent functional status
Male gender
Table 4  Multivariable logistic regression analysis for ICH within 30 
days after surgery (n = 72)
Bold p-values below 0.05 were considered as statistically significant
ASA American Society of Anesthesiologists, CI confidence interval, 
SIRS systematic inflammatory response syndrome
a Inflated β-coefficients to odds ratio per 60 min increase
Predictor Definition ICH
OR 95% CI p value
ASA classification I–II Ref – –
III 1.45 0.74–3.11 0.31
IV–V 3.23 1.50–7.59 0.004
Hypertension 2.27 1.38–3.75 0.001
Weight loss 4.42 1.48–10.67 0.003
Bleeding disorder 3.13 1.16–7.09 0.01
Preoperative SIRS 2.45 0.98–5.21 0.05
Preoperative sodium 135–145 Ref – –
< 135 2.41 1.29–4.26 0.004
> 145 1.14 0.06–5.59 0.90
Operative time Minutes 1.20a 1.07–1.33 < 0.001
141J Neurooncol (2018) 136:135–145 
1 3
profile depends on the type of VTE (DVT vs. PE events) and 
the clinical setting (hospitalized vs. post-discharge patients).
The patient population in this study was technically clas-
sified as all those with primary malignant brain tumors 
based on ICD-9 codes. Gliomas represent close to 80% of 
primary malignant brain tumors [38], however, there is no 
standard ICD-9 code specific for glioma. The Central Brain 
Tumor Registry of the United States (CBTRUS) argues that 
multiple combinations of ICD histology codes can be used 
to define gliomas, and their approach was modeled in this 
study [38]. Therefore, these results are primarily applicable 
to glioma patients and should be put in the context of previ-
ous outcome research on glioma patients.
Previous work
Several multicenter studies have previously investigated the 
short-term incidence of and risk factors for VTE after brain 
tumor surgery [3, 13, 39–45], of which four studies focused 
on glioma patients [3, 13, 39, 41]. From these studies, the 
rate of VTE following craniotomy is cited as 3.3–7.5% for 
glioma patients [3, 13, 39, 41] and 2.3–4.0% for brain tumors 
patients in general [11, 40–42, 44], with a follow-up ranging 
from solely the initial hospital stay to 6 weeks after surgery. 
The 30-day VTE rate was as high as 9.3% when asympto-
matic DVTs were included too [3]. These results are com-
parable to the VTE rates found in the current study and sug-
gest a higher rate of VTE in glioma patients postoperatively 
compared to other brain tumors.
Simanek et al. assessed the cumulative incidence of VTE 
over time after craniotomy for gliomas, demonstrating a 
major increase in the number of events in the first 3 months 
after surgery; however, no granular insight into the distribu-
tion of events within the first few weeks postoperatively was 
provided due to a low sample size. Neither did this study 
stratify for VTE type or the clinical setting of the patient [4].
Risk factors identified for VTE after craniotomy for glio-
mas are older age, history of craniotomy, history of VTE, 
coagulopathy, seizures, increased stay on the intensive care 
unit, prolonged hospital stay, residual tumor tissue, and 
absence of thromboprophylactic therapy [3, 4, 6, 12–15]. 
Missios et al. stratified for VTE type demonstrating different 
risk profiles for postoperative DVT and PE. Male gender, 
Hispanic ethnicity, and medium bed size were predictive 
for PE, whereas chronic heart failure was predictive for 
DVT [3]. Other predictors of postoperative VTE identified 
in the broader group of brain tumor patients were higher 
BMI, hypertension, functional dependence, lower Karnofsky 
Performance Scale (KPS) score, motor deficits, ventilator 
dependence, steroid usage, preoperative sepsis, longer oper-
ative times, and higher World Health Organization (WHO) 
tumor grade [11, 40, 42, 43, 46].
Prophylactic anticoagulation is a commonly used strategy 
to prevent VTE but should be carefully balanced against the 
risk of ICH. In previous studies, the rates of ICH follow-
ing craniotomy for brain tumors is cited as 1.0–4.0% with a 
follow-up ranging between the initial hospital stay and long-
term survival after surgery [6, 13–15, 44, 46–48]. However, 
definitions for major ICH varied between volumetric meas-
urement of the hematoma, presence of symptoms, decrease 
in hemoglobin, or need for surgical evacuation of hematoma 
[14, 15, 21, 23, 24, 49].
Mantia et al. assessed the cumulative incidence of ICH 
over time after craniotomy for glioma. However, no time-
to-event analysis was provided for the direct postoperative 
period due to a low sample size [23]. Neither did this study 
stratify for the clinical setting of the patient. Risk factors 
associated with ICH were history of craniotomy, use of 
bevacizumab, and therapeutic anticoagulation for VTE [13, 
20–24]. The association between thromboprophylactic anti-
coagulation and ICH remains to be elucidated [15].
To our knowledge, the current study is the first large mul-
ticenter assessment including a descriptive time-to-event 
analysis for both VTE and ICH within 30 days after crani-
otomy for primary malignant brain tumors. Additionally, it 
is the first study that uses the NSQIP database to identify 
predictors of ICH after brain tumor resection. By addressing 
thrombotic outcomes as well as hemorrhagic outcomes, this 
study provides a meaningful direction for future research on 
thromboprophylactic treatment strategies. Lastly, the large 
sample size allows a stratification of both the descriptive and 
inferential analysis, demonstrating differences in risk profile 
and incidence over time based on VTE type (DVT vs. PE) 
and clinical setting (hospitalized vs. post-discharge patients).
Limitations
Complication rates found in the current study can be con-
servative estimates if events were not reported back to the 
hospitals. VTEs were only coded as events if they were 
diagnosed and treated, thereby missing asymptomatic and 
undetected VTEs. The database additionally lacks several 
demographic variables identified in other studies as predic-
tors. Tumor specific information (histology, size, location, 
residual tumor volume) and complication specific informa-
tion (location and classification of DVT, PE, and ICH) was 
not available. However, both VTE and ICH were defined in 
the NSQIP database as complications requiring medical and 
surgical treatment, respectively, resulting in selection of the 
most clinically relevant events. Perhaps most importantly, no 
data is available regarding anticoagulation status and non-
pharmaceutical prophylactic methods. Therefore, this study 
offers limited insight in the efficacy of different thrombopro-
phylactic treatment strategies and their association with the 
occurrence of ICH. Selection bias can be introduced since 
142 J Neurooncol (2018) 136:135–145
1 3
institutions can selectively contribute patients to the NSQIP 
registry. There was a lower number of events due to separate 
analyses based on VTE type and clinical setting; however, 
our study was not underpowered for most outcome meas-
ures according to rule of 10 events per variable in the multi-
variable analysis [50]. Lastly, VTE and ICH events after the 
30-day time period established in NSQIP are not accounted 
for in this study, although studies have demonstrated that 
the risk of VTE events remains non-negligible beyond 30 
days postoperatively with incidences up to 26% in the first 
12 months postoperatively [4–6]. Despite these limitations, 
this study provides useful insight into the rates, timing, and 
predictors of DVT, PE, and ICH after craniotomy for pri-
mary malignant brain tumors. Due to the multicenter nature 
of the NSQIP dataset, the results of this study may be more 
representative of typical management at all hospitals, includ-
ing but not limited to tertiary care academic centers.
Implications
The significant prevalence of VTE and ICH following crani-
otomy for primary malignant brain tumors found in the cur-
rent study indicates that there is still room for improvement 
when it comes to monitoring and preventing these events. 
Rolston et al. demonstrated that the prevalence of VTE fol-
lowing a neurosurgical procedure registered in NSQIP has 
remained consistent over the last years [51]. This suggests 
that perioperative management still hasn’t improved effec-
tively with regards to preventing VTE, despite the attention 
it receives in neurosurgical literature.
These results particularly encourage the need for contin-
ued awareness for VTE post-discharge, especially for PE, 
which has more lethal consequences. These PEs can also 
be considered more sudden since they were less often pre-
ceded by a known DVT. PEs preceded by a DVT, however, 
suggest inadequate treatment for the initial VTE event. It is 
possible that DVTs are less frequent post-discharge. It is our 
primary suspicion, however, that DVTs are underdetected 
after leaving the hospital because they are less frequently 
symptomatic and cannot be effectively screened for. It is 
also possible that patients develop symptomatic DVTs but 
are unaware of the signs and symptoms until they progress 
to PE, implicating a possible role for improved patient edu-
cation in preventing morbidity caused by DVT and PE. In 
prospective randomized control trials investigating different 
VTE prophylaxis modalities, Goldhaber et al. screened all 
craniotomy patients prior to discharge and found 9.3% of 
patients to have VTE, most of which were asymptomatic in 
both studies [45].
Most guidelines recommend that prophylactic use of 
low-molecular weight heparin or unfractionated heparin 
should be considered in all cancer patients undergoing 
major surgery [16–19]. In patients undergoing operations 
for brain tumors, however, the benefits of anticoagulation 
should be carefully balanced against the risk of ICH [52, 
53]. Although most guidelines support the use of pharma-
cological prophylaxis in patients with brain tumors, proper 
timing of prophylaxis remains controversial and the use of 
anticoagulation often depends on the surgeon’s preference 
[52–54]. Recommendations vary between administration 
throughout hospitalization [19], up to 7–10 days after sur-
gery [16, 17, 55], until the patient is mobile [52], or timing 
based on the individual risk profile [56]. A lack of scientific 
evidence is primarily the cause of this variation in recom-
mendations. Recent systematic reviews and meta-analyses 
of VTE prophylaxis in patients undergoing craniotomy for 
brain tumors have been performed [42, 57–60]. These analy-
ses have compared different VTE prophylaxis modalities, as 
well as their safety and cost effectiveness, but they do not 
thoroughly investigate the efficacy of prophylaxis over time 
to determine a recommended duration. Only one clinical 
trial studied the effect of continued prophylaxis up to 12 
months after surgery [15]. No significant association was 
found between prolonged prophylaxis and the rate of both 
VTE and ICH; however, the trial was stopped early because 
of expiration of study medication, and the control group 
received placebo instead of short-term prophylaxis. Many 
patients may not need or benefit from continuing throm-
boprophylactic therapy beyond discharge. Algattas et al. 
reviewed the safety and effectiveness of thromboprophylac-
tic strategies and indicated that different regimens may have 
different efficacies depending on the patient’s VTE risk pro-
file [57]. This highlights the importance of using the appro-
priate risk profile for optimizing postoperative management.
Since the NSQIP data does not contain information on 
thromboprophylactic strategies, the current study provides 
limited insight into the efficacy or safety of prophylactic 
anticoagulation and insufficient evidence to change the 
current clinical practice of thromboprophylaxis in patients 
undergoing operations for primary malignant brain tumors. 
Therefore, we concur with the current guidelines that rec-
ommend pharmaceutic prophylaxis (low-molecular weight 
heparin or unfractionated heparin) in combination with 
mechanical prophylaxis (anti-embolism stockings or inter-
mittent pneumatic compression devices) postoperatively 
until the end of hospitalization or until the patient is mobile. 
Absolute contra-indications for these include recent ICH or 
another active major bleeding [16–19, 52, 53, 55, 56].
Suggestions for future research
Despite its limitations, this study provides useful insight 
into the prevalence, timing, and risk factors of postoperative 
VTE and ICH after craniotomy for primary malignant brain 
tumors. The results of the current study demonstrate that 
there is still room for improvement, especially with regard to 
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the prevention of PE after hospitalization. The distinct criti-
cal time periods for both thrombotic and hemorrhagic events 
suggest a potentially safe and effective role for continuing 
prophylactic anticoagulation post-discharge in high-risk 
patients. Additionally, the typical patient at risk for develop-
ing a VTE during hospitalization is not the same as the typi-
cal patient at risk for developing a VTE post-discharge. This 
is crucial for tailoring post-discharge management to the 
risk profile of the individual patient and suggests an impor-
tant direction for future research. Therefore, future research 
should study the effects of timing of thromboprophylactic 
therapy, screening for asymptomatic events, and the effects 
of patient education on the occurrence of VTE and/or ICH. 
Additionally, future studies should construct prediction mod-
els for DVT, PE, and ICH and examine the effectiveness of 
tailoring postoperative thromboprophylaxis to the individual 
risk profile of patients undergoing craniotomy for primary 
malignant brain tumors.
Conclusion
The increased risk of VTE experienced by patients with 
primary malignant brain tumors extends beyond the period 
of hospitalization, especially for PE, whereas ICH occurs 
predominantly in the first few days after surgery. The risk 
profile for VTE depends on the type of VTE and the clinical 
setting of the patient. VTE can have fatal consequences if 
not recognized early, therefore clinicians should have high 
suspicion during the postoperative period and a low thresh-
old for specific monitoring and prevention.
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